Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lattanzi

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Expert Review of Anticancer Therapy|June 20, 2020
The emerging role of antibody-drug conjugates in urothelial carcinomaMichael Lattanzi, Jonathan E Rosenberg
Current Oncology Reports|February 27, 2019
Current Status and Future Direction of Immunotherapy in Urothelial CarcinomaMichael Lattanzi, Arjun V Balar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2022
Reply to S. ZhangMichael Lattanzi, Samuel A Funt, Jonathan E Rosenberg
Journal of Clinical Medicine|October 26, 2024
Clinical Meaningfulness of an Algorithm-Based Service for Analyzing Treatment Response in Patients with Metastatic Cancer Using FDG PET/CTManojkumar Bupathi, Benjamin Garmezy, Michael Lattanzi, et al.
Journal for Immunotherapy of Cancer|May 19, 2018
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysisMichael Lattanzi, Joseph Han, Una Moran, et al.
Journal for Immunotherapy of Cancer|October 5, 2018
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancyMichael Lattanzi, Fang-Ming Deng, Luis A Chiriboga, et al.
Cancer Immunology Research|November 9, 2019
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk MelanomaAnna Pavlick, Ana B Blazquez, Marcia Meseck, et al.
Journal of the National Cancer Institute|June 19, 2018
Primary Melanoma Histologic Subtype: Impact on Survival and Response to TherapyMichael Lattanzi, Yesung Lee, Danny Simpson, et al.
JCO Oncology Practice|June 16, 2025
Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer ResearchMichal Sternschuss, Michael Lattanzi, Emily Vertosick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World ExperienceBrendan J Guercio, Michal Sarfaty, Min Yuen Teo, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Expert Review of Anticancer Therapy|June 20, 2020
The emerging role of antibody-drug conjugates in urothelial carcinomaMichael Lattanzi, Jonathan E Rosenberg
Current Oncology Reports|February 27, 2019
Current Status and Future Direction of Immunotherapy in Urothelial CarcinomaMichael Lattanzi, Arjun V Balar
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2022
Reply to S. ZhangMichael Lattanzi, Samuel A Funt, Jonathan E Rosenberg
Journal of Clinical Medicine|October 26, 2024
Clinical Meaningfulness of an Algorithm-Based Service for Analyzing Treatment Response in Patients with Metastatic Cancer Using FDG PET/CTManojkumar Bupathi, Benjamin Garmezy, Michael Lattanzi, et al.
Journal for Immunotherapy of Cancer|May 19, 2018
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysisMichael Lattanzi, Joseph Han, Una Moran, et al.
Journal for Immunotherapy of Cancer|October 5, 2018
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancyMichael Lattanzi, Fang-Ming Deng, Luis A Chiriboga, et al.
Cancer Immunology Research|November 9, 2019
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk MelanomaAnna Pavlick, Ana B Blazquez, Marcia Meseck, et al.
Journal of the National Cancer Institute|June 19, 2018
Primary Melanoma Histologic Subtype: Impact on Survival and Response to TherapyMichael Lattanzi, Yesung Lee, Danny Simpson, et al.
JCO Oncology Practice|June 16, 2025
Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer ResearchMichal Sternschuss, Michael Lattanzi, Emily Vertosick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World ExperienceBrendan J Guercio, Michal Sarfaty, Min Yuen Teo, et al.
Pageof 2